SEC Form 4 · accession 0001562180-18-005028
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Gale Oltmans
Officer — General Counsel
Period of report
Dec 14, 2018
Accepted (ET)
Dec 18, 2018 · 7:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 16, 2018 | M | 7,000 | $0.00 | A | 7,000 | D | |
| Common StockF2 | Dec 16, 2018 | F | 3,079 | $15.97 | D | 3,921 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Dec 14, 2018 | A | 19,375 | A | — | Dec 20, 2022 | Common Stock | 19,375 | 19,375 | D |
| Stock Option (Right to Buy)F4 | $15.97 | Dec 14, 2018 | A | 116,250 | A | — | Dec 16, 2028 | Common Stock | 116,250 | 116,250 | D |
| Restricted Stock UnitsF5 | $0.00 | Dec 16, 2018 | M | 7,000 | D | — | Dec 17, 2021 | Common Stock | 7,000 | 21,000 | D |
Explanation of responses
- F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs.
- F2Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F3RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019.
- F4The options vest in four equal annual installments beginning on December 16, 2019.
- F5The RSUs vested and were settled in common stock on December 16, 2018.